- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Evolus Inc (EOLS)
Evolus Inc stock price live, this page displays NASDAQ EOLS stock exchange data. View the EOLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Evolus Inc real time stock price chart below.
What Is the Evolus Inc Stock Price Today?
The Evolus Inc stock price today is 5.20.
What Is the Stock Symbol for Evolus Inc?
The stock symbol for Evolus Inc is "EOLS."
What Stock Exchange Does Evolus Inc Trade On?
Evolus Inc is listed and trades on the NASDAQ stock exchange.
Is Evolus Inc a Good Stock to Buy?
Determining whether Evolus Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EOLS quote. (ISIN: US30052C1071)
What Is the Evolus Inc Stock Price Today?
The Evolus Inc stock price today is 5.20.
What Is the Stock Symbol for Evolus Inc?
The stock symbol for Evolus Inc is "EOLS."
What Stock Exchange Does Evolus Inc Trade On?
Evolus Inc is listed and trades on the NASDAQ stock exchange.
Is Evolus Inc a Good Stock to Buy?
Determining whether Evolus Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EOLS quote. (ISIN: US30052C1071)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.90
5.24
52 wk Range
4.74
17.12
EOLS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.905.24
52 wk Range
4.7417.12
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EOLS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
17.83
Upside
+242.95%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Evolus CEO Moatazedi sells $75k in shares
- Investing.com
- Evolus Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Evolus Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Avelar Rui, Evolus officer, sells $16k in EOLS stock
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Evolus Inc Company Profile
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus Inc SWOT Analysis
Aesthetic Expansion | Evolus enters the hyaluronic acid dermal filler market with FDA-approved Evolysse, potentially increasing its addressable market by 78% to $6 billion |
Financial Milestones | Explore Evolus's journey to profitability, with Q3 2024 revenue of $61 million and ambitious targets of $700 million revenue by 2028 |
Market Dynamics | Delve into the "Ozempic effect" driving filler demand and how Evolus's cold cross-linking technology positions it against established competitors |
Growth Trajectory | Analysts project $16-$27 price targets, with fillers expected to contribute 8-10% of 2025 revenue, signaling potential for significant market expansion |
Evolus Inc Earnings Call Summary for Q3/2025
- Evolus reported Q3 2025 revenue of $69 million (+13% YoY), exceeding forecasts despite missing EPS expectations (-$0.24 vs -$0.15 forecast), with stock closing up 6.4%.
- Jeuveau maintained 14% U.S. market share while Evolisse launch contributed $15.5 million in revenue, positioning Evolus as the third-largest toxin brand in a challenging aesthetic market.
- Gross margin reached 66.5% (67.6% adjusted) with non-GAAP operating loss improving to $3.1 million from $6.7 million in 2024.
- Management projects 2025 revenue of $295-305 million (11-15% growth), with profitability expected by year-end and sustainable profitability in 2026.
- FDA approval for Sculpt injectable product is anticipated in 2026, representing a key growth initiative amid market saturation and competitive pressures.
Last Updated: 2025-11-05, 08:06 p/m
Read Full TranscriptCompare EOLS to Peers and Sector
Metrics to compare | EOLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEOLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.8x | 7.1x | −0.6x | |
PEG Ratio | −16.72 | 0.14 | 0.00 | |
Price/Book | −11.7x | 2.5x | 2.6x | |
Price / LTM Sales | 1.2x | 2.5x | 3.4x | |
Upside (Analyst Target) | 275.0% | 21.0% | 41.5% | |
Fair Value Upside | Unlock | 30.8% | 5.5% | Unlock |
Analyst Ratings
6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.83
(+242.95% Upside)
Earnings
Latest Release
Nov 05, 2025
EPS / Forecast
-0.24 / -0.15
Revenue / Forecast
69.00M / 67.69M
People Also Watch
FAQ
What Is the Evolus (EOLS) Stock Price Today?
The Evolus stock price today is 5.20
What Stock Exchange Does Evolus Trade On?
Evolus is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Evolus?
The stock symbol for Evolus is "EOLS."
What Is the Evolus Market Cap?
As of today, Evolus market cap is 337.06M.
What Is Evolus's Earnings Per Share (TTM)?
The Evolus EPS (TTM) is -0.91.
When Is the Next Evolus Earnings Date?
Evolus will release its next earnings report on Mar 11, 2026.
From a Technical Analysis Perspective, Is EOLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Evolus Stock Split?
Evolus has split 0 times.
How Many Employees Does Evolus Have?
Evolus has 329 employees.
What is the current trading status of Evolus (EOLS)?
As of Jan 20, 2026, Evolus (EOLS) is trading at a price of 5.20, with a previous close of 5.20. The stock has fluctuated within a day range of 4.90 to 5.24, while its 52-week range spans from 4.74 to 17.12.
What Is Evolus (EOLS) Price Target According to Analysts?
The average 12-month price target for Evolus is USD17.83333, with a high estimate of USD20 and a low estimate of USD10. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +242.95% Upside potential.
What Is the EOLS After Hours Price?
EOLS's last after hours stock price is 5.14, the stock has decreased by -0.06, or -1.15%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.